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Background: As lung function declines rapidly in the early stages of chronic obstructive pulmonary disease (COPD),
the effects of bronchodilators in patients with moderate disease and those who have not previously received
maintenance therapy are of interest. OTEMTO® 1 and 2 were two replicate, 12-week, Phase III studies investigating
the benefit of tiotropium + olodaterol on lung function and quality of life in patients with moderate to severe
disease. Post hoc analyses were performed to assess the benefits for patients according to disease severity and
treatment history.
Methods: Four subgroup analyses were performed: Global initiative for chronic Obstructive Lung Disease (GOLD)
2/3, GOLD A/B/C/D, treatment naive/not treatment naive and receiving inhaled corticosteroids (ICS) at baseline/not
receiving ICS at baseline. Primary end points were change in forced expiratory volume in 1 s (FEV1) area under the
curve from 0 to 3 h response, change in trough FEV1 and St George’s Respiratory Questionnaire (SGRQ) total score.
Transition Dyspnoea Index (TDI) focal score was a secondary end point, and SGRQ and TDI responder analyses were
further end points; all were assessed at 12 weeks.
Results: In all subgroups, patients receiving tiotropium + olodaterol responded better overall than those receiving
tiotropium monotherapy. Improvements with tiotropium + olodaterol over placebo or tiotropium monotherapy
were noted across GOLD 2/3 and GOLD A/B/C/D; however, improvements in SGRQ total score were most evident
in the GOLD B subgroup. Moreover, lung-function outcomes were generally greater in those patients who had
been receiving previous long-acting bronchodilator and/or ICS maintenance treatment.
Conclusions: These data suggest that tiotropium + olodaterol should be considered as a treatment option in
patients with moderate COPD who are initiating maintenance therapy, as well as those with more severe disease.
Trial registration: ClinicalTrials.gov: NCT01964352 and NCT02006732.
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The use of long-acting β2-agonists (LABAs) and long-
acting muscarinic antagonists (LAMAs) is central to the
pharmacological management of patients with chronic
obstructive pulmonary disease (COPD) [1, 2]. The aim
of treatment is to improve lung function, reduce symp-
toms and risk of exacerbations, and improve health
status [1].
Tiotropium is an established once-daily LAMA that
improves lung function, patient-reported outcomes such
as dyspnoea and quality of life, and reduces exacerba-
tions in patients with COPD [3–9]. Olodaterol is a novel
LABA that provides 24-h bronchodilation and symptom-
atic benefits in patients with COPD [10–13]. The com-
bination of tiotropium + olodaterol has been extensively
studied in a large Phase III clinical trial programme that
demonstrated improvements in lung function and
patient-reported outcomes compared to tiotropium
monotherapy, with tolerability similar to tiotropium
[14–18]. A recent post hoc analysis of the TONADO®
studies showed that tiotropium + olodaterol significantly
improved lung function in Global initiative for chronic
Obstructive Lung Disease (GOLD) severity groups 2, 3
and 4, compared to monotherapy, irrespective of
whether patients had received prior LAMA or LABA
maintenance treatment [19].
The OTEMTO® studies were two replicate, randomised,
double-blind, Phase III studies investigating the effects of
tiotropium + olodaterol on lung function and quality of
life [16]. Unlike the TONADO® trials, OTEMTO® included
a placebo arm as well as tiotropium as an active com-
parator in order to properly understand the effect size of
tiotropium + olodaterol on patient-reported outcomes.
Overall, tiotropium + olodaterol was superior to tiotro-
pium at improving quality of life as measured by the St
George’s Respiratory Questionnaire (SGRQ) and, import-
antly, the improvement versus placebo was >4 units (the
minimum clinically important difference) [16].
The OTEMTO® studies provided the opportunity to
study the effectiveness of tiotropium + olodaterol in dif-
ferent COPD subgroups based on lung function (GOLD
2 or 3), GOLD combined assessment (A, B, C or D) and
previous treatment focusing on treatment-naive patients
(no prior use of LAMAs, LABAs and/or inhaled corti-
costeroids [ICS]). We, therefore, performed post hoc
analyses to evaluate the efficacy of tiotropium + oloda-
terol compared to placebo and tiotropium monotherapy
in subgroups of patients defined by GOLD category
(GOLD 2–3 and GOLD A–D) and by previous treat-
ment history (treatment naive and baseline ICS use)
after 12 weeks of treatment. The aim of this analysis
was to understand if the benefits of tiotropium + oloda-
terol vary according to GOLD categorisation or previ-
ous treatment.Methods
Study design
As presented elsewhere [16], OTEMTO® 1 (1237.25;
NCT01964352) and 2 (1237.26; NCT02006732) were
two replicate, double-blind, placebo-controlled studies.
Patients were randomised to one of four treatment arms
to receive once-daily tiotropium+ olodaterol 2.5/5 μg, tio-
tropium+ olodaterol 5/5 μg, tiotropium 5 μg or placebo,
all delivered via the Respimat® inhaler.
Patients
Patients were included if they were aged ≥40 years
with moderate or severe COPD (GOLD 2–3; post-
bronchodilator forced expiratory volume in 1 s [FEV1]
<80 % and ≥30 % of predicted normal), FEV1/forced
vital capacity <70 % predicted and a smoking history
of >10 pack-years. Exclusion criteria included signifi-
cant disease other than COPD, a history of asthma,
COPD exacerbation or symptoms of lower respiratory
tract infection within the previous 3 months.
Patients continued their ICS therapy if they were on a
stable dose for 6 weeks prior to screening but were not
permitted to take LAMAs or LABAs other than study
medication. Short-acting muscarinic antagonists were
permitted only during the screening period and open-
label salbutamol was provided as rescue medication for
use throughout the study.
The studies were conducted in accordance with the
Declaration of Helsinki, International Conference on
Harmonisation Harmonised Tripartite Guideline for Good
Clinical Practice and local regulations. Signed, informed
consent was obtained from all patients. The studies were
approved by the relevant Institutional Review Board/Inde-
pendent Ethics Committees and competent authorities; full
details are included in Additional file 1.
Outcomes
There were three primary end points in the OTEMTO®
studies, all at 12 weeks: SGRQ total score, change from
baseline in trough FEV1 and change from baseline in
FEV1 area under the curve from 0 to 3 h (AUC0–3).
Mahler Transition Dyspnoea Index (TDI) focal score
was a secondary end point; responder analyses for SGRQ
and TDI focal scores were further end points.
Assessments
As described in the primary manuscript [16], pulmonary
function tests were performed at 1 h pre-dose, 10 min pre-
dose, 5, 15 and 30 min post-dose and 1, 2 and 3 h post-
dose at baseline and week 12, and at 10 min pre-dose only
after 2 and 6 weeks of treatment. The final trough FEV1
measurement was taken the day after the week 12 visit (at
23 h and 23 h 50 min post-dose). SGRQ was completed in
the clinic at baseline and weeks 6 and 12. At weeks 6 and
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asks patients about breathlessness compared to baseline.
Subgroup analysis
For all of the post hoc analyses presented here, data from
OTEMTO® 1 and 2 were combined to increase the robust-
ness of the analyses. As tiotropium+ olodaterol 5/5 μg is
the licensed dose, we are only presenting the results of
these subgroup analyses for the tiotropium + oloda-
terol 5/5 μg, tiotropium 5 μg and placebo groups.
Four subgroup analyses were performed: GOLD 2 or 3,
GOLD A–D (based on the modified Medical Research
Council dyspnoea scale), maintenance treatment naive (no
prior use of LAMAs, LABAs and/or ICS) and baseline use
of ICS. Results are presented for the three primary end
points (FEV1 AUC0–3 response, trough FEV1 response and
SGRQ total score), the SGRQ responder analysis, TDI focal
score and TDI focal score responder analysis.
For the SGRQ responder analysis, patients were
classed as responders if their SGRQ total score improved
from baseline to week 12 by ≥4 units. Odds ratios were
calculated between groups using a logistical regression
including the fixed categorical effect of treatment. A re-
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once in the treated setrepeated measures approach was used for the analysis of
continuous end points, including the fixed categorical ef-
fects of treatment, test day and treatment-by-test-day
interaction, as well as the continuous fixed covariates of
baseline and baseline-by-test-day interaction.
The TDI responder analysis was based on the TDI
focal score; patients were classed as responders if they
had a value that was ≥1.0 unit.
As these analyses are post hoc and performed within
subgroups with potentially small sample sizes, they are
not powered for statistical comparisons within sub-
groups; therefore, results are presented as forest plots of
treatment differences with corresponding 95 % confi-
dence intervals (CIs). Differences in treatment effects be-
tween subgroups are discussed and emphasis is not put
on statistical significance within subgroups alone
(assessed based on the 95 % CI). No adjustment for mul-
tiple comparisons has been performed.
Results
Patient disposition and baseline characteristics
In OTEMTO® 1 and 2, a total of 1623 patients were ran-
domised, with 1621 receiving treatment and 1525 com-
pleting the study (Fig. 1). Patient demographics anded
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tion are shown in Table 1. Overall baseline characteris-
tics such as age and sex were similar across subgroups.
As expected, mean FEV1 values and baseline pulmonary
medications also differed between subgroups. Patients
who were already receiving maintenance therapy tended
to be ex-smokers and to have worse lung function com-
pared to those who were treatment naive.
Efficacy
GOLD 2 and 3 subgroups
Trough FEV1 responses and SGRQ total scores im-
proved with tiotropium + olodaterol in both GOLD 2
and 3 subgroups after 12 weeks of treatment compared
to baseline (Figs. 2 and 3). In the GOLD 2 subgroup,
the adjusted mean (standard error) SGRQ total score
change from baseline at week 12 was −4.7 (0.6) in the
tiotropium + olodaterol 5/5 μg arm, −2.2 (0.6) in the
tiotropium 5 μg arm and −0.7 (0.6) in the placebo arm.
In the GOLD 3 subgroup, the adjusted mean (standard
error) SGRQ total score change from baseline at week 12
was −5.6 (0.8) in the tiotropium + olodaterol 5/5 μg arm,
−4.2 (0.9) in the tiotropium 5 μg arm and 0.5 (0.9) in the
placebo arm. Similar improvements were also seen in the
absolute SGRQ score (Additional file 1: Table S1).
Improvements after 12 weeks compared to baseline were
also observed for tiotropium + olodaterol 5/5 μg in the
GOLD 2 and 3 subgroups for FEV1 AUC0–3 response
(292–326 mL) and TDI (1.67–1.85) (Additional file 1:
Table S1).
Treatment differences are shown in Fig. 4 for FEV1
AUC0–3, trough FEV1 responses, SGRQ total score and
TDI focal score. In general, results in GOLD 2 patients
were similar to GOLD 3, with larger CIs for GOLD 3 due
to the smaller number of patients in this group. The com-
parison of tiotropium + olodaterol versus placebo showed
significant treatment effects for all end points in GOLD 2
and 3 patients (95 % CI did not cross zero). The compari-
sons of tiotropium+ olodaterol versus tiotropium showed
significant differences between treatment for most end
points, except for trough FEV1, in both GOLD 2 and 3,
and, as discussed, SGRQ in GOLD 3 patients, which is
most likely due to the reduced sample size as treatment dif-
ferences are similar between the groups.
GOLD A–D subgroups
Tiotropium + olodaterol was more effective at improving
FEV1 AUC0–3 than tiotropium monotherapy and placebo
in GOLD A–D subgroups (Fig. 5). Trough FEV1 re-
sponses improved significantly with tiotropium + oloda-
terol compared to placebo in GOLD A–D subgroups.
Improvements with tiotropium + olodaterol were numer-
ically better compared to tiotropium monotherapy in
GOLD A, B and D groups, although these improvementswere not significant, as the 95 % CI crossed zero. In gen-
eral, lung-function treatment comparisons were similar
across GOLD A–D subgroups.
SGRQ total score and TDI focal score improved signifi-
cantly, to a greater extent with tiotropium + olodaterol
compared to placebo in GOLD A–D groups (Fig. 5b and
c). Treatment effects were similar between subgroups with
overlapping 95 % CIs. When comparing tiotropium+ olo-
daterol to tiotropium alone, treatment effects differed be-
tween subgroups and improvements in SGRQ total score
were most evident in the GOLD B subgroup.
Treatment-naive patients
Tiotropium + olodaterol was more effective than tiotro-
pium monotherapy and placebo for FEV1 AUC0–3 and
trough FEV1, both in patients with and without previous
maintenance therapy, although for trough FEV1 the
95 % CI crossed zero for the comparison with tiotro-
pium in treatment-naive individuals. The effect sizes
were generally greater in those patients who had been
receiving previous maintenance therapy (Fig. 6a). The
mean improvements in SGRQ total score and TDI focal
score were similar for patients with and without previ-
ous maintenance therapy and significant for both treat-
ment comparisons (Fig. 6b and c).
ICS use at baseline
Tiotropium + olodaterol was more effective at improving
lung-function outcomes than tiotropium monotherapy
and placebo, both in patients who were receiving ICS
treatment at baseline and those who were not. FEV1
AUC0–3 and trough FEV1 responses improved in both
groups (Fig. 7a), with some evidence for a superior re-
sponse for patients receiving ICS at baseline. Baseline
SGRQ scores were higher for patients receiving ICS
treatment at baseline, compared to those not receiving
baseline ICS (44.4 and 41.5, respectively). In contrast to
lung-function outcomes, the improvement in SGRQ
total scores with tiotropium + olodaterol compared to
tiotropium or placebo was greater in patients who were
not receiving ICS at baseline (Fig. 7b and c).
Responder analyses across subgroups
Responder analyses for SGRQ total score demonstrated
that a greater proportion of patients responded with tio-
tropium + olodaterol compared to tiotropium monother-
apy or placebo for all subgroups (Additional file 1:
Figure S1a) with significant improvements compared to
placebo in all subgroups except GOLD A. Overall, treat-
ment differences for tiotropium + olodaterol compared
to tiotropium monotherapy or placebo were similar be-
tween subgroups, with widely overlapping 95 % CIs. In
the GOLD 2 subgroup, 52.8 % of patients in the tiotro-
pium + olodaterol 5/5 μg arm and 39.2 % in the
Table 1 Patient demographics and baseline characteristics by subgroups and overall (combined OTEMTO® 1 and 2; treated set)
GOLD 2 GOLD 3 GOLD A GOLD B GOLD C GOLD D Naive: no Naive: yes ICS: no ICS: yes Overall
Patients, n 1042 570 486 483 250 400 943 678 1013 608 1621
Male, n (%) 609 (58.4) 374 (65.6) 298 (61.3) 271 (56.1) 167 (66.8) 250 (62.5) 574 (60.9) 413 (60.9) 632 (62.4) 355 (58.4) 987 (60.9)
Mean (SD) age, years 64.3 (8.7) 65.5 (7.9) 64.3 (8.1) 64.4 (9.0) 65.2 (8.6) 65.4 (7.9) 65.6 (8.2) 63.5 (8.6) 63.9 (8.4) 66.1 (8.3) 64.7 (8.4)
Smoking status, n (%)
Ex-smoker 554 (53.2) 300 (52.6) 260 (53.5) 255 (52.8) 135 (54.0) 207 (51.8) 560 (59.4) 298 (44.0) 473 (46.7) 385 (63.3) 858 (52.9)
Current smoker 488 (46.8) 270 (47.4) 226 (46.5) 228 (47.2) 115 (46.0) 193 (48.3) 383 (40.6) 380 (56.0) 540 (53.3) 223 (36.7) 763 (47.1)
Mean (SD) pre-bronchodilator
FEV1, L 1.557 (0.460) 0.969 (0.262) 1.617 (0.469) 1.499 (0.445) 1.094 (0.353) 0.988 (0.327) 1.283 (0.459) 1.436 (0.521) 1.422 (0.512) 1.221 (0.428) 1.347 (0.492)
Mean (SD) post-bronchodilator
FEV1, L 1.754 (0.468) 1.146 (0.274) 1.820 (0.472) 1.690 (0.455) 1.269 (0.370) 1.167 (0.336) 1.476 (0.475) 1.619 (0.532) 1.614 (0.522) 1.406 (0.444) 1.536 (0.504)
FEV1 % predicted 62.94 (7.98) 41.09 (5.54) 63.66 (8.08) 62.09 (7.72) 44.86 (9.80) 42.58 (9.06) 53.91 (12.86) 56.75 (12.57) 56.65 (12.55) 52.52 (12.83) 55.10 (12.81)
FEV1/FVC ratio, % (SD) 54.54 (8.21) 42.82 (9.62) 54.66 (8.33) 54.54 (8.14) 44.13 (9.83) 43.79 (10.24) 48.49 (10.42) 52.87 (9.89) 51.87 (9.96) 47.74 (10.67) 50.32 (10.42)
Baseline pulmonary medication, n (%)
Any 761 (73.0) 473 (83.0) 349 (71.8) 356 (73.7) 213 (85.2) 321 (80.3) 943 (100) 297 (43.8) 632 (62.4) 608 (100) 1240 (76.5)
ICS 337 (32.3) 269 (47.2) 131 (27.0) 173 (35.8) 125 (50.0) 179 (44.8) 608 (64.5) 0 (0.0) 0 (0.0) 608 (100) 608 (37.5)
LAMA 334 (32.1) 221 (38.8) 157 (32.3) 150 (31.1) 105 (42.0) 148 (37.0) 560 (59.4) 0 (0.0) 277 (27.3) 283 (46.5) 560 (34.5)
SAMA 68 (6.5) 56 (9.8) 24 (4.9) 38 (7.9) 21 (8.4) 41 (10.3) 88 (9.3) 36 (5.3) 55 (5.4) 69 (11.3) 124 (7.6)
LABA 365 (35.0) 261 (45.8) 149 (30.7) 184 (38.1) 117 (46.8) 179 (44.8) 629 (66.7) 0 (0.0) 144 (14.2) 485 (79.8) 629 (38.8)
SABA 470 (45.1) 343 (60.2) 211 (43.4) 223 (46.2) 159 (63.6) 224 (56.0) 542 (57.5) 276 (40.7) 447 (44.1) 371 (61.0) 818 (50.5)
GOLD A–D based on modified Medical Research Council dyspnoea scale. The inclusion criteria for this study only included patients with GOLD 2 or 3 disease; however, 8 patients were classed as GOLD 4 and 1 patient
as GOLD 1 based on entrance spirometry results. As this is a small number, these patients were not included in the GOLD 2/3 subgroup analysis and are not included in the table
GOLD Global initiative for chronic Obstructive Lung Disease, ICS inhaled corticosteroids, SD standard deviation, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, LAMA long-acting muscarinic antagonist,
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Fig. 2 Adjusted mean trough FEV1 responses at 12 weeks in patients with GOLD 2 and 3 disease. FEV1: forced expiratory volume in 1 s;
GOLD: Global initiative for chronic Obstructive Lung Disease; SE: standard error; T: tiotropium; O: olodaterol
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to 33.7 % in the placebo arm. In the GOLD 3 subgroup,
51.7 % of patients in the tiotropium + olodaterol 5/5 μg
arm and 45.0 % in the tiotropium 5 μg arm were SGRQ
responders, compared to 28.5 % in the placebo arm.



































Fig. 3 Adjusted mean SGRQ total score at 12 weeks in patients with GOLD
GOLD: Global initiative for chronic Obstructive Lung Disease; SE: standard eresponders with tiotropium + olodaterol compared to
tiotropium monotherapy and placebo in all subgroups,
with similar treatment effect overall (Additional file 1:
Figure S1b). Improvements were significant compared to
placebo in all subgroups and compared to tiotropium
for most of the subgroups.GOLD 3
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Fig. 4 (a) FEV1 AUC0–3 and trough FEV1 responses, (b) SGRQ total score and (c) TDI focal score, all at 12 weeks: treatment comparisons for T + O
5/5 μg versus T 5 μg and versus placebo in patients with GOLD 2 and 3 disease. FEV1: forced expiratory volume in 1 s; AUC0–3: area under the
curve from 0–3 h; SGRQ: St George’s Respiratory Questionnaire; TDI: Transition Dyspnoea Index; T: tiotropium; O: olodaterol; GOLD: Global
initiative for chronic Obstructive Lung Disease; CI: confidence interval
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Fig. 5 (a) FEV1 AUC0–3 and trough FEV1 responses, (b) SGRQ total score and (c) TDI focal score, all at 12 weeks: treatment comparisons for T + O
5/5 μg versus T 5 μg and versus placebo in patients with GOLD A–D disease. FEV1: forced expiratory volume in 1 s; AUC0–3: area under the curve
from 0–3 h; SGRQ: St George’s Respiratory Questionnaire; TDI: Transition Dyspnoea Index; T: tiotropium; O: olodaterol; GOLD: Global initiative for
chronic Obstructive Lung Disease; CI: confidence interval
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Fig. 6 (a) FEV1 AUC0–3 and trough FEV1 responses, (b) SGRQ total score and (c) TDI focal score: treatment comparisons at 12 weeks for T + O
5/5 μg versus T 5 μg and versus placebo in patients who were treatment naive/not treatment naive at baseline. FEV1: forced expiratory volume in
1 s; AUC0–3: area under the curve from 0–3 h; SGRQ: St George’s Respiratory Questionnaire; TDI: Transition Dyspnoea Index; T: tiotropium;
O: olodaterol; CI: confidence interval
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Fig. 7 (a) FEV1 AUC0–3 and trough FEV1 responses, (b) SGRQ total score and (c) TDI focal score: treatment comparisons at 12 weeks for T + O
5/5 μg versus T 5 μg and versus placebo in patients who were receiving/ not receiving ICS treatment at baseline. FEV1: forced expiratory volume
in 1 s; AUC0–3: area under the curve from 0–3 h; SGRQ: St George’s Respiratory Questionnaire; TDI: Transition Dyspnoea Index; T: tiotropium;
O: olodaterol; ICS: inhaled corticosteroids; CI: confidence interval
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The OTEMTO® studies demonstrated that tiotropium +
olodaterol improved lung function and quality of life in
patients with moderate to severe COPD. Subgroup ana-
lyses confirm that tiotropium + olodaterol is equally ef-
fective in patients with moderate COPD (GOLD 2), as
for those with severe disease (GOLD 3). Using the
GOLD A–D categorisation, tiotropium + olodaterol
showed a similar effect on lung function in all the sub-
groups but the benefit of this dual bronchodilator com-
bination versus tiotropium monotherapy on patient-
reported outcomes was most apparent in GOLD B pa-
tients. Tiotropium + olodaterol was also superior to tio-
tropium monotherapy irrespective of previous treatment
history, even in those patients naive to all maintenance
therapy.
The responder analyses are an alternative way of un-
derstanding the treatment effects on patient-reported
outcomes. Importantly, there was a greater proportion
of SGRQ and TDI responders with tiotropium + oloda-
terol compared to tiotropium in GOLD 2 patients, dem-
onstrating the potential benefits of tiotropium +
olodaterol in terms of quality of life for patients with
moderate disease.
Post hoc analyses of the TONADO® studies showed
that tiotropium + olodaterol was superior to tiotropium
and olodaterol monotherapies for lung-function changes
in patient subgroups classified by lung-function impair-
ment severity, age and previous treatment history [19].
Our analyses generally agree with these previous find-
ings on lung function and further extend these observa-
tions by investigating responses in patients with GOLD
A–D disease, as well as investigating patient-reported
outcomes. The analysis of patients with GOLD A–D dis-
ease showed that the effects of tiotropium + olodaterol
on lung function versus tiotropium monotherapy or pla-
cebo were similar in all subgroups. However, for SGRQ,
the benefit of tiotropium + olodaterol was most apparent
in GOLD B patients. There has been some debate about
which patients with COPD benefit most from dual
bronchodilator treatment compared to long-acting
bronchodilator monotherapy. The current findings in
GOLD B patients suggest that the symptomatic benefit
of tiotropium + olodaterol is greater in patients with
higher baseline symptoms and FEV1 >50 % predicted
and this may indicate that early combined treatment
would be beneficial for these patients. The treatment
difference was less pronounced in GOLD D patients
compared to GOLD B patients, suggesting that in highly
symptomatic patients with COPD (i.e. GOLD B and D)
the greatest benefit of LAMA + LABA compared to
long-acting bronchodilator monotherapy on patient-
reported outcomes is in patients with less severe airflow
obstruction, although all groups showed benefit fromLAMA + LABA therapy. A note of caution for this in-
terpretation of the GOLD A–D analysis is that the pa-
tients were split into four subgroups, thereby producing
the smallest sample size of all the analyses presented
here, and this reduced sample size may influence these
results.
There was a trend towards greater lung-function im-
provements with tiotropium + olodaterol in patients who
had received previous maintenance therapy. However,
this pattern did not translate to a greater benefit on
patient-reported outcomes. The mean treatment effects
were similar in both groups of patients and the wide
95 % CI for the treatment effect in patients receiving
previous maintenance treatment suggests a large vari-
ation between individuals in this group, and results may
have been influenced by selection bias. Overall, we con-
clude that treatment with tiotropium + olodaterol
showed evidence of similar efficacy, irrespective of previ-
ous maintenance treatment.
In this study, there was a large proportion of patients
receiving ICS treatment at baseline, the majority of
whom were classed as having severe or very severe
(GOLD 3 or GOLD C/D) disease. This is in accordance
with current GOLD guidelines, which recommend ICS
treatment for patients with severe/very severe COPD
and frequent exacerbations who are not adequately con-
trolled with long-acting bronchodilators [1]. Clinical tri-
als of LAMA + LABA combinations usually allow
patients receiving ICS treatment to continue during the
study. This is mostly for ethical reasons, as stepping pa-
tients down from both long-acting bronchodilator treat-
ment and ICS in the placebo arm is potentially unsafe.
However, the use of LAMA + LABA combination in-
halers in real life is likely to be mostly without concomi-
tant ICS treatment. Although this sub-analysis of
OTEMTO® cannot exclude an effect of ICS treatment
on the clinical response to tiotropium + olodaterol, it
would appear that any effect, if present, is small. Further
studies are required to better assess whether patients
with GOLD D disease should be treated with LAMA +
LABA or LAMA + LABA + ICS.
The main limitations of these analyses are that they
are post hoc and not powered for statistical comparisons
between subgroups. However, as the analyses were per-
formed to confirm that the positive results of the
OTEMTO® study hold true for patients of all disease se-
verities included, and for patients irrespective of prior
medication use, this is not a major concern. A pattern of
results for the lung-function changes noted in this sub-
group analysis is that often the 95 % CI for tiotropium +
olodaterol versus tiotropium crossed zero for trough
FEV1 but not for FEV1 AUC0–3. This, again, is likely to
be related to sample size for these subgroups and the
greater effect size for AUC0–3.
Singh et al. Respiratory Research  (2016) 17:73 Page 12 of 13One reason why it is of interest to examine the ben-
efits of tiotropium + olodaterol in patients by disease
severity, and in patients who are treatment naive, is
that the fastest decline in lung function in COPD is
seen in the initial stages of the disease [20]. Thus,
selecting the most appropriate treatment for initial
therapy may be important. Even in mild to moderate
COPD, patients start to limit exercise and activities,
which are further limited as lung function declines,
leading to a sedentary lifestyle [21]. It has been sug-
gested that intervening early in COPD may benefit pa-
tients, as they are able to maintain levels of activity
and health [20], and treatment may improve health-
related quality of life and potentially slow disease pro-
gression [22]. Furthermore, a subgroup analysis of the
UPLIFT® tiotropium study showed that in patients
with GOLD 2 (moderate) COPD, early intervention
with tiotropium appeared to slow the course of FEV1
decline [23]. Improvements in lung function are asso-
ciated with better quality of life and reduced symp-
toms [24]. By targeting earlier disease, it is hoped that
treatment may maintain the patient’s functionality and
postpone disease progression for longer.Conclusions
Overall, the added benefits of tiotropium + olodaterol
compared to tiotropium monotherapy in patients with
moderate COPD and treatment-naive patients suggest
that tiotropium + olodaterol should be considered as an
option for patients at the point where there is a need to
initiate maintenance therapy, as well as in patients with
more severe disease.Additional file
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